title: Toward biosynthetic design and implementation of Escherichia coli-derived paclitaxel and other heterologous polyisoprene compounds.
abstract: Escherichia coli offers unparalleled engineering capacity in the context of heterologous natural product biosynthesis. However, as with other heterologous hosts, cellular metabolism must be designed or redesigned to support final compound formation. This task is at once complicated and aided by the fact that the cell does not natively produce an abundance of natural products. As a result, the metabolic engineer avoids complicated interactions with native pathways closely associated with the outcome of interest, but this convenience is tempered by the need to implement the required metabolism to allow functional biosynthesis. This review focuses on engineering E. coli for the purpose of polyisoprene formation, as it is related to isoprenoid compounds currently being pursued through a heterologous approach. In particular, the review features the compound paclitaxel and early efforts to design and overproduce intermediates through E. coli.
authors.affiliation: Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, New York, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Jiang
authors.forename: Gregory
authors.initials: G
authors.lastname: Stephanopoulos
authors.forename: Blaine A
authors.initials: BA
authors.lastname: Pfeifer
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism*; D053898:Biosynthetic Pathways / Q000235:genetics*; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism*; D060847:Metabolic Engineering; D017239:Paclitaxel / Q000378:metabolism*; D013729:Terpenes / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D013729:Terpenes; D017239:Paclitaxel